Phage Biobank: Present Challenges and Future Perspectives

Curr Opin Biotechnol. 2021 Apr;68:221-230. doi: 10.1016/j.copbio.2020.12.018. Epub 2021 Feb 10.

Abstract

After a century of use in human infection, the preparation and administration of therapeutic bacteriophages (phages) still relies on ad hoc partnerships of researchers, biotech companies, clinicians and regulators. There is a clear need to improve the reproducibility, safety and speed of the provision of suitable phages. Here we discuss the specific characteristics and challenges of a sustainable phage biobank and, as we build a national consortium aimed at delivering phage therapeutics, suggest a roadmap toward national biobanking and phage therapy initiatives using the Australian context as a model.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Australia
  • Bacteriophages*
  • Biological Specimen Banks
  • Humans
  • Phage Therapy*
  • Reproducibility of Results